+

TN2009000452A1 - [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof - Google Patents

[4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof

Info

Publication number
TN2009000452A1
TN2009000452A1 TNP2009000452A TN2009000452A TN2009000452A1 TN 2009000452 A1 TN2009000452 A1 TN 2009000452A1 TN P2009000452 A TNP2009000452 A TN P2009000452A TN 2009000452 A TN2009000452 A TN 2009000452A TN 2009000452 A1 TN2009000452 A1 TN 2009000452A1
Authority
TN
Tunisia
Prior art keywords
pharmaceutical compositions
quinazolin
thiophen
dioxo
methylamino
Prior art date
Application number
TNP2009000452A
Other languages
English (en)
Inventor
Emma Sharp
Louisa Jane Quegan
Anjali Pandey
Juan Wang
Matthew Nieder
Wolin Huang
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of TN2009000452A1 publication Critical patent/TN2009000452A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TNP2009000452A 2007-05-02 2009-10-30 [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof TN2009000452A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92732807P 2007-05-02 2007-05-02
PCT/US2008/062584 WO2008137809A2 (fr) 2007-05-02 2008-05-02 Sels de [4(-(6-fluoro-7-méthylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phényl]-5-chloro-thiophén-2-yl-sulfonylurée, formes et procédés qui leur sont associés

Publications (1)

Publication Number Publication Date
TN2009000452A1 true TN2009000452A1 (en) 2011-03-31

Family

ID=39651344

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000452A TN2009000452A1 (en) 2007-05-02 2009-10-30 [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof

Country Status (18)

Country Link
US (1) US20090042916A1 (fr)
EP (1) EP2076510A2 (fr)
JP (1) JP2010526105A (fr)
KR (1) KR20100020455A (fr)
CN (1) CN101720324A (fr)
AU (1) AU2008247457A1 (fr)
BR (1) BRPI0810800A2 (fr)
CA (1) CA2686221A1 (fr)
CO (1) CO6241155A2 (fr)
EA (1) EA200901474A1 (fr)
EC (1) ECSP099779A (fr)
GT (1) GT200900282A (fr)
IL (1) IL201829A0 (fr)
MA (1) MA31397B1 (fr)
MX (1) MX2009011836A (fr)
TN (1) TN2009000452A1 (fr)
WO (1) WO2008137809A2 (fr)
ZA (1) ZA200907493B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2428514A1 (fr) * 2005-11-03 2012-03-14 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substitution-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-péenyl]-5-chloro-thiophène-2-yl-sulfonylurées et formes et procédés correspondants
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
WO2011006169A1 (fr) 2009-07-10 2011-01-13 Portola Pharmaceuticals, Inc. Méthodes de diagnostic et de traitement de troubles thrombotiques médiés par cyp2c19*2
US20130165459A1 (en) * 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (fr) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Formes galéniques de l'élinogrel et leurs méthodes d'administration injectables
CN103339126B (zh) * 2010-12-03 2016-06-29 博尔托拉制药公司 式(i)化合物的固态形式及其药物组合物、剂型和使用方法
CN106777526B (zh) * 2016-11-25 2020-05-01 江苏大学 基于遗传算法的高温高压离心式叶轮多学科优化方法
WO2019126557A1 (fr) 2017-12-22 2019-06-27 Aesthetics Biomedical, Inc. Composition de conservation biologique et procédés d'utilisation
US10933096B2 (en) 2017-12-22 2021-03-02 Aesthetics Biomedical, Inc. Biologic preserving composition and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847925A (en) * 1971-07-15 1974-11-12 En Nom Collectif Science Et Ci Benzenesulfonyl semicarbazides
DE3134780A1 (de) * 1981-09-02 1983-03-10 Hoechst Ag, 6000 Frankfurt "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung"
US4720450A (en) * 1985-06-03 1988-01-19 Polaroid Corporation Thermal imaging method
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
US20020025961A1 (en) * 2000-02-04 2002-02-28 Scarborough Robert M. Platelet ADP receptor inhibitors
ATE502928T1 (de) * 2000-11-01 2011-04-15 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US6824790B2 (en) * 2002-01-09 2004-11-30 Enzrel Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
US20040242658A1 (en) * 2003-01-08 2004-12-02 Dr. Reddy's Laboratories Limited Amorphous form of rosiglitazone maleate and process for preparation thereof
KR20060113700A (ko) * 2003-10-03 2006-11-02 포톨라 파마슈티컬스, 인코포레이티드 2,4-디옥소-3-퀴나졸리닐아릴 설포닐우레아
EP2428514A1 (fr) * 2005-11-03 2012-03-14 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substitution-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-péenyl]-5-chloro-thiophène-2-yl-sulfonylurées et formes et procédés correspondants
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
CA2686203A1 (fr) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Dosage oral et intraveineux de l'inhibiteur p2y12 reversible et a action directe

Also Published As

Publication number Publication date
EP2076510A2 (fr) 2009-07-08
IL201829A0 (en) 2010-06-16
US20090042916A1 (en) 2009-02-12
CO6241155A2 (es) 2011-01-20
ZA200907493B (en) 2010-07-28
JP2010526105A (ja) 2010-07-29
KR20100020455A (ko) 2010-02-22
ECSP099779A (es) 2010-01-29
BRPI0810800A2 (pt) 2014-10-29
MA31397B1 (fr) 2010-05-03
EA200901474A1 (ru) 2010-04-30
WO2008137809A2 (fr) 2008-11-13
WO2008137809A3 (fr) 2009-01-22
AU2008247457A1 (en) 2008-11-13
CA2686221A1 (fr) 2008-11-13
GT200900282A (es) 2010-05-21
MX2009011836A (es) 2010-05-20
CN101720324A (zh) 2010-06-02

Similar Documents

Publication Publication Date Title
WO2007056219A3 (fr) [(2,4-dioxo-1,4-dihydro-2h-quinazoline-3-yl)-phenyle]-5-chloro-thiophene-2-yl-sulfonylurees [4-(6-halo-7-substitutees)] et formes et procedes associes
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
WO2006119507A3 (fr) Composition non nucleotidique et technique d'inhibition d'agregation de plaquettes
TN2009000444A1 (en) Combination therapy with a compound acting as a plateletadp receptor inhibitor
WO2008008539A3 (fr) Dérivés hétérocycliques condensés et procédés d'utilisation
WO2010108074A3 (fr) Inhibiteurs de pi3 kinase
ATE517882T1 (de) Chinolinderivate
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
WO2008019967A3 (fr) Dérivés phényliques, de la pyridine et de la quinoléine
WO2007096151A3 (fr) Composes organiques
WO2008094992A3 (fr) Inhibiteurs de kinase
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA201692214A1 (ru) Вещества, связывающие ядерные рецепторы
MX346186B (es) Inhibidores de proteina cinasas.
WO2009120660A3 (fr) Pyridoxazines substituées
TW200738729A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
HK1133596A1 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
EA201100391A1 (ru) Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы
ZA200806778B (en) N-Hydroxyacrylamide compounds
WO2007032028A8 (fr) Thiazolinones et oxazolinones et leur utilisation en tant qu'inhibiteurs de ptp1b
WO2009030952A3 (fr) Composés hétérocycliques et leurs procédés d'utilisation
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
WO2009025785A3 (fr) Ligands de récepteur cb2 pour le traitement de la douleur
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载